The Journal of Clinical Pharmacology

Cover image for Vol. 54 Issue 6

June 2014

Volume 54, Issue 6

Pages i–vi, 603–718

  1. Issue Information

    1. Top of page
    2. Issue Information
    3. Editor's Choice: Minireview
    4. Continuing Education: Clinical Trials
    5. Pediatric Pharmacology
    6. Drug-Food Interactions
    7. Drug Development
    8. Biomarkers
    9. Pharmacokinetics
    1. Issue Information (pages i–vi)

      Version of Record online: 3 MAY 2014 | DOI: 10.1002/jcph.313

  2. Editor's Choice: Minireview

    1. Top of page
    2. Issue Information
    3. Editor's Choice: Minireview
    4. Continuing Education: Clinical Trials
    5. Pediatric Pharmacology
    6. Drug-Food Interactions
    7. Drug Development
    8. Biomarkers
    9. Pharmacokinetics
    1. Topical microbicides and HIV prevention in the female genital tract (pages 603–615)

      Mackenzie L. Cottrell and Angela D.M. Kashuba

      Version of Record online: 28 MAR 2014 | DOI: 10.1002/jcph.292

  3. Continuing Education: Clinical Trials

    1. Top of page
    2. Issue Information
    3. Editor's Choice: Minireview
    4. Continuing Education: Clinical Trials
    5. Pediatric Pharmacology
    6. Drug-Food Interactions
    7. Drug Development
    8. Biomarkers
    9. Pharmacokinetics
  4. Pediatric Pharmacology

    1. Top of page
    2. Issue Information
    3. Editor's Choice: Minireview
    4. Continuing Education: Clinical Trials
    5. Pediatric Pharmacology
    6. Drug-Food Interactions
    7. Drug Development
    8. Biomarkers
    9. Pharmacokinetics
    1. Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults (pages 619–629)

      Chenguang Wang, Karel Allegaert, Dick Tibboel, Meindert Danhof, Caroline D. van der Marel, Ron A.A. Mathot and Catherijne A.J. Knibbe

      Version of Record online: 23 JAN 2014 | DOI: 10.1002/jcph.259

  5. Drug-Food Interactions

    1. Top of page
    2. Issue Information
    3. Editor's Choice: Minireview
    4. Continuing Education: Clinical Trials
    5. Pediatric Pharmacology
    6. Drug-Food Interactions
    7. Drug Development
    8. Biomarkers
    9. Pharmacokinetics
    1. You have full text access to this OnlineOpen article
    2. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin (pages 649–656)

      Joseph M. Custodio, Hui Wang, Jia Hao, Eve-Irene Lepist, Adrian S. Ray, Jessica Andrews, Kah Hiing J. Ling, Andrew Cheng, Brian P Kearney and Srinivasan Ramanathan

      Version of Record online: 17 JAN 2014 | DOI: 10.1002/jcph.256

  6. Drug Development

    1. Top of page
    2. Issue Information
    3. Editor's Choice: Minireview
    4. Continuing Education: Clinical Trials
    5. Pediatric Pharmacology
    6. Drug-Food Interactions
    7. Drug Development
    8. Biomarkers
    9. Pharmacokinetics
    1. You have full text access to this OnlineOpen article
      Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects (pages 665–674)

      Daniel A. Spyker, Polina Voloshko, Eugene R. Heyman and James V. Cassella

      Version of Record online: 22 JAN 2014 | DOI: 10.1002/jcph.257

  7. Biomarkers

    1. Top of page
    2. Issue Information
    3. Editor's Choice: Minireview
    4. Continuing Education: Clinical Trials
    5. Pediatric Pharmacology
    6. Drug-Food Interactions
    7. Drug Development
    8. Biomarkers
    9. Pharmacokinetics
    1. Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors (pages 682–687)

      Vasiliki Thomeas, Selina Chow, Jose O. Gutierrez, Sanja Karovic, Kristen Wroblewski, Emily Kistner-Griffin, Theodore G. Karrison and Michael L. Maitland

      Version of Record online: 17 JAN 2014 | DOI: 10.1002/jcph.254

  8. Pharmacokinetics

    1. Top of page
    2. Issue Information
    3. Editor's Choice: Minireview
    4. Continuing Education: Clinical Trials
    5. Pediatric Pharmacology
    6. Drug-Food Interactions
    7. Drug Development
    8. Biomarkers
    9. Pharmacokinetics
    1. Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride (pages 688–695)

      Feifan Xie, Zeneng Cheng, Sanwang Li, Xingling Liu, Xin Guo, Peng Yu and Zhenkun Gu

      Version of Record online: 22 JAN 2014 | DOI: 10.1002/jcph.261

    2. Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites (pages 696–706)

      Daniele Ouellet, Ekaterina Gibiansky, Cathrine Leonowens, Anne O'Hagan, Patricia Haney, Julie Switzky and Vicki L. Goodman

      Version of Record online: 17 JAN 2014 | DOI: 10.1002/jcph.263

    3. Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studies (pages 707–718)

      Hongmei Xu, Anja Henningsson, Sofie Alverlind, Raj Tummala, Steven Toler, Jessica S. Beaver and Nidal Al-Huniti

      Version of Record online: 16 JAN 2014 | DOI: 10.1002/jcph.264

SEARCH

SEARCH BY CITATION